Innovation Pathways: How to Leverage Clinical Trials for Innovation

Abstract

Purpose

This paper explores the multifaceted role of clinical trials as pivotal drivers of innovation, creativity, and entrepreneurship within the medical and healthcare sectors, with a particular focus on the unique landscape and burgeoning potential of the African continent. It aims to synthesize current trends, identify challenges, highlight opportunities, and propose actionable policy recommendations to leverage clinical trials for sustainable healthcare advancement in Africa and globally.

Findings

Clinical trials are foundational to medical progress, increasingly transformed by digital technologies and AI for enhanced efficiency and patient-centricity. Despite Africa bearing a significant global disease burden, it remains critically underrepresented in global clinical trials, leading to a lack of tailored interventions. However, robust regional clinical research infrastructure and a growing ecosystem of African-led innovations in pharmaceuticals, medical devices, and digital health demonstrate immense potential. Regulatory harmonization efforts, spearheaded by the African Medicines Agency (AMA) and the African Medicines Regulatory Harmonization (AMRH) initiative, are streamlining processes, though challenges in funding, ethical oversight, and consistent capacity persist. Public-private partnerships and increasing venture capital interest are crucial, yet sustainable domestic investment and equitable collaboration remain key to unlocking Africa's full innovative capacity.

Research Limitations/Implications

The primary limitation is the reliance on publicly available aggregated data, which may not capture the full scope of all clinical trial activities or granular details of their innovative outputs across all African nations. Future research should focus on detailed case studies of successful African-led trials, quantitative analysis of their economic impact, and longitudinal studies on the effectiveness of harmonized regulatory frameworks. The implications suggest a need for more localized data collection and reporting mechanisms to better inform policy and investment.

Practical Implications

For policymakers, the findings underscore the urgency of increasing domestic R&D investment, fast-tracking regulatory harmonization, and fostering an enabling environment for health tech entrepreneurship. For researchers, it highlights the importance of patient-centric trial design, ethical conduct, and robust community engagement. For industry, it points to significant untapped market potential and the imperative of inclusive trial design to develop globally relevant, locally appropriate health solutions.

Social Implications

Leveraging clinical trials for innovation in Africa can significantly improve health equity by ensuring access to safe, effective, and culturally appropriate medical products. It fosters local scientific talent, creates employment opportunities, and builds resilient health systems capable of addressing both existing and emerging health challenges, thereby enhancing global health security.

Originality/Value

This paper provides a timely and comprehensive synthesis of the current state and future trajectory of clinical trials as drivers of innovation in the African healthcare context. It uniquely integrates perspectives on technological advancements, regulatory evolution, funding dynamics, and ethical considerations, offering a holistic framework for stakeholders to foster a vibrant, self-reliant, and globally impactful African health innovation ecosystem.

Keywords: Clinical Trials, Innovation, Healthcare, Entrepreneurship, Africa, Digital Health, Artificial Intelligence, Regulatory Harmonization, Public-Private Partnerships, Health Equity.

Article Type: Original Research

1. Introduction

1.1. Background: The Imperative of Healthcare Innovation in Africa

Africa faces a profound and complex health landscape, characterized by a disproportionately high burden of disease. The continent accounts for approximately 25% of the global disease burden, yet a striking imbalance exists in global health research, with only 1.1% of clinical trials worldwide hosted in Africa in 2023.1 This significant underrepresentation in clinical research has far-reaching implications, extending beyond the continent's borders to impact global health security. When new treatments and procedures are not thoroughly tested across diverse populations, particularly those with distinct genetic and racial profiles, there is a critical lack of empirical data to support their safety and efficacy for African individuals.3 This absence of localized evidence directly contributes to delays in the approval and availability of new treatments on the continent, limiting access to potentially life-saving interventions tailored to African needs.1

The COVID-19 pandemic served as a stark reminder of these vulnerabilities within African health systems, underscoring the urgent necessity for self-sufficiency in vaccine manufacturing and clinical trial capacity.4 The pandemic highlighted that relying solely on external solutions can leave populations exposed during global health crises. This experience has intensified the focus on building robust, homegrown innovation pathways to ensure that Africa can proactively address its health challenges. The prevailing disparity in disease burden versus research representation creates a compelling "innovation imperative" for Africa. This means that developing and strengthening its own research and development capabilities, with clinical trials at their core, is not merely beneficial but essential for the continent's health sovereignty and its contribution to global medical advancements.

1.2. Clinical Trials as a Cornerstone of Medical Advancement

Clinical trials represent the bedrock of modern medicine, serving as meticulously designed medical research studies involving human participants. Their primary objective is to rigorously test new treatments and procedures, evaluating their safety, efficacy, potential side effects, and overall impact on patients' quality of life.5 These trials are indispensable for contemporary medicine, providing invaluable insights into the appropriate use and optimal dosing of new drugs.6 They play a crucial role in improving public health outcomes, identifying more cost-effective treatment options that can reduce healthcare expenditures, and fostering a deeper understanding of underlying disease biology.6

Beyond their role in validating new interventions, clinical trials are fundamental to the practice of Evidence-Based Medicine (EBM). The reliability and quality of systematic reviews and meta-analyses, which synthesize existing research to inform clinical guidelines, are often directly dependent on the number and rigor of the clinical trials they encompass.6 This signifies that clinical trials are not just a final step in the drug development process but are dynamic engines of both validation and discovery. They go beyond simply proving or disproving a hypothesis; they actively generate new knowledge, uncover unforeseen biological mechanisms, and can even reveal novel applications for existing drugs through processes like drug repurposing, as demonstrated during the COVID-19 pandemic with the evaluation of antiviral therapies.6 This dual function positions clinical trials as a powerful catalyst for continuous innovation and discovery, where scientific theory is translated into practical application, and new ideas are constantly refined and brought to fruition.

1.3. Purpose of the Paper

This paper aims to elucidate how clinical trials can be strategically leveraged to foster innovation, creativity, and entrepreneurship within Africa's medical and healthcare sectors. It will analyze the current landscape, identify key challenges and opportunities, and propose actionable recommendations for stakeholders to cultivate a robust and self-sustaining health innovation ecosystem, relevant both continentally and globally.

2. The Evolving Landscape of Clinical Trials and Innovation

2.1. Defining Clinical Trials and Their Foundational Role in Innovation

Traditionally, clinical trials have been perceived primarily as a critical, albeit often lengthy, process for validating the safety and efficacy of new medical interventions. They are indeed the "cornerstone of delivering the next wave of life-changing medicines," providing the essential evidence base for regulatory approvals and clinical recommendations.5 However, the understanding and practice of clinical trials are undergoing a significant transformation, moving beyond a static validation process to become dynamic innovation hubs themselves.

Modern clinical innovation extends to the very design and delivery of trials, emphasizing patient-centricity to enhance the experience for both participants and site teams.7 This shift means that the trial process itself is a source of continuous improvement. For instance, assessing outcomes, whether positive, negative, or neutral, directly informs national governing bodies like NICE on whether an intervention should be recommended for use.5 This feedback loop contributes to a more agile and responsive healthcare system. The emphasis on improving the patient experience through innovative trial design and delivery demonstrates a proactive approach to research. This evolution positions clinical trial sites not merely as testing grounds but as integral components of the broader healthcare innovation ecosystem, actively contributing to research and development through their design, data generation, and direct patient engagement.

2.2. Technological Advancements Revolutionizing Clinical Trials (e.g., AI, Digital Health, Wearables)

The landscape of clinical research is being profoundly reshaped by rapid technological advancements, creating unprecedented opportunities for efficiency, precision, and accessibility. Clinical research technology encompasses a broad array of digital tools, platforms, and systems that modernize every phase of clinical trials, from initial design to data analysis.8 Key innovations driving this revolution include electronic data capture, wearable devices, artificial intelligence (AI), telehealth platforms, and cloud-based analytics. These technologies are collectively transforming traditional paper-based studies into highly connected, data-driven research environments.8

Wearable devices, for example, have moved beyond simple step counters to enable continuous monitoring and real-time data collection of patients' health journeys. This provides a "full-length movie" of health progression, offering a far richer and more dynamic understanding than the "snapshots" provided by traditional, infrequent clinic visits.8 This enhanced data richness allows for more precise insights into disease progression and the real-world impact of investigational medicines.7

Artificial intelligence is playing a particularly transformative role. AI systems can process vast and complex datasets, including genomic data from thousands of patients, real-time wearable data, and medical imaging, simultaneously.8 This capability is revolutionizing drug development by optimizing various aspects of clinical trials. For instance, AI can significantly improve patient recruitment by analyzing over 40,000 clinical research sites globally and predicting enrollment success with up to 85% accuracy, ensuring more diverse and representative cohorts.7 Furthermore, AI is accelerating the assessment of outcome events. Tools like AstraZeneca's AIDA (Automating Identification Detection Adjudication) use AI and machine learning to assess the certainty of adjudication, potentially shortening study timelines by up to five months for events like cardiovascular death.7 Digital tools, such as AstraZeneca's "Unify" mobile application, further streamline the patient experience by integrating virtual consultations, medication reminders, and patient-reported outcomes into a single platform.7

The integration of these technologies fundamentally alters the possibilities of clinical research. They make trials more agile, data-rich, and potentially more inclusive, which is especially pertinent for regions like Africa where geographical distances and resource constraints can be mitigated by digital solutions. This digital transformation is not merely an incremental improvement; it represents a qualitative leap in how clinical research is conducted, making it more efficient, precise, and ultimately, more capable of delivering new treatments to patients faster.

3. Clinical Trials as Catalysts for Innovation and Entrepreneurship in Africa

3.1. Current State of Clinical Trial Infrastructure and Capacity in Africa

Africa possesses a steadily maturing and expanding clinical trial infrastructure, supported by a growing network of research centers and specialized organizations. Over the past 25 years, the International AIDS Vaccine Initiative (IAVI) has forged partnerships with over 40 clinical research centers across more than 14 African countries, including Gabon, Ghana, Kenya, Liberia, Mozambique, Nigeria, Rwanda, Senegal, Sierra Leone, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe.9 These centers have been instrumental in pioneering Phase 1 HIV vaccine trials, consistently adhering to the highest international standards.9 This long-standing collaboration has cultivated a robust foundation for vaccine development and epidemiological studies on the continent.

African Contract Research Organizations (CROs) are also demonstrating significant capabilities. ACE Research, for instance, operates as a "OneStop" solution across 45 African countries, showcasing impressive success rates: 95% for ethics committee approvals within 60 days, 90% for site activation within 45 days, and a remarkable 93% subject retention rate.10 This operational efficiency is supported by access to over 40 high-enrolling research sites and more than 1000 hospitals with diverse patient populations.10 Their expertise spans critical areas, including infectious diseases and biothreats such as Malaria, Tuberculosis, HIV/AIDS, Ebola, Lassa fever, and COVID-19, and is increasingly expanding into non-communicable diseases like cardiovascular, metabolic, hematology, and oncology.10

Leading national research institutions further bolster Africa's clinical trial capacity. The Kenya Medical Research Institute (KEMRI), established in 1979, operates a Centre for Clinical Research (CCR) that has been conducting Phase I-IV clinical trials since 1985.11 KEMRI's activities extend to diagnostic and therapeutic services, capacity building, and recently, hosting Artificial Intelligence and Machine Learning (AI/ML) workshops for drug discovery, indicating a forward-looking approach to technological integration in research.14 In South Africa, the Desmond Tutu Health Foundation (DTHF) has been a pioneer in HIV/AIDS research and care for two decades, notably being the first public clinic in the country to provide antiretroviral therapy (ART) in the 1990s.15 Their research encompasses HIV prevention (including PrEP and vaccines), treatment adherence, tuberculosis, sexually transmitted infections, adolescent health, and non-communicable diseases. Similarly, the Aurum Institute, with sites in South Africa and Mozambique, has completed over 200 clinical trials and research studies in 18 years, enrolling over 67,500 participants in studies focused on HIV prevention, tuberculosis innovation, and COVID-19 response.18

The presence of highly skilled principal investigators and a diverse talent pool, including laboratory technologists, clinical trial managers, and medical professionals, underscores the significant human capital within these African research networks.9 This maturing infrastructure and homegrown expertise indicate a crucial shift. Africa is not merely a passive site for externally-driven trials; it is developing into a capable and increasingly self-reliant hub for global health research. This growing capacity allows the continent to address its own unique health challenges effectively and contribute meaningfully to global medical knowledge, moving towards a position of greater scientific and health sovereignty.

Table 1: Key Clinical Research Organizations and Initiatives in Africa

This table provides a concise, high-level overview of major organizations and initiatives actively engaged in clinical research across Africa. It serves to quickly illustrate the breadth and depth of the continent's existing infrastructure, highlighting key focus areas, geographic reach, and notable achievements. This structured presentation allows readers to readily grasp the institutional landscape and the significant contributions being made to advance health research and innovation on the continent.

3.2. Challenges and Opportunities in the African Clinical Trial Ecosystem

Despite the burgeoning infrastructure and expertise, the African clinical trial ecosystem faces a unique set of challenges that simultaneously present significant opportunities for growth and strategic development.

Challenges:

A persistent and critical challenge is the severe under-representation of Africa in global clinical trials. In 2023, the continent, which bears a quarter of the global disease burden, hosted only 1.1% of worldwide clinical trials.1 This disparity is particularly stark in pivotal late-stage trials, with only 27.5% of such projects from top pharmaceutical companies including one or more African countries in 2024.2 This exclusion translates directly into a lack of safety and efficacy data for African populations, delaying access to new treatments and hindering the development of locally tailored interventions.1

Furthermore, there is a limited disease focus among pharmaceutical companies operating in Africa. Their research and development footprint often remains concentrated on a narrow range of infectious diseases, such as HIV, tuberculosis, and malaria.1 This overlooks the growing toll of non-communicable diseases (NCDs) like cancer, diabetes, and cardiovascular conditions, which are increasingly prevalent on the continent. For example, Africa accounts for over 80% of global sickle cell disease cases, yet there are currently no gene therapy trials for this condition in Africa.1

Regulatory and ethical hurdles also impede trial conduct. The heterogeneous nature of national regulatory landscapes and varying maturity levels of National Regulatory Authorities (NRAs) can create complexities for sponsors seeking to conduct multi-country trials.3 Research Ethics Committees (RECs) often grapple with inadequate funding, staffing, and training, which can lead to a disproportionate focus on scientific and budgetary aspects over nuanced ethical considerations.28 Concerns about the independence of RECs can also arise when their operations are closely tied to the funding of the institutions whose research they review.29

Informed consent processes present unique complexities, particularly in regions with high rates of underage mothers or significant linguistic diversity. Vague regulations regarding consent for children of minor parents can affect participant rights and trial generalizability.30 In West Africa, where many local languages are primarily oral and lack written forms, ensuring genuine comprehension of complex medical information, rather than mere compliance, is a substantial ethical and practical challenge.31

Finally, significant funding and capacity gaps persist. There is often inadequate national-level funding for clinical trials, and a scarcity of established researchers with the expertise to consistently compete for large international grants and lead multi-center studies.32 Individual investments in research capacity often yield "transactional gains" that are not sustained over time due to a lack of overall coordination across the ecosystem.36 Challenges also extend to supply chains for clinical research materials, further complicating trial logistics.33

Opportunities:

Despite these challenges, Africa's unique context presents significant opportunities. The high disease burden, while a major public health challenge, paradoxically offers a vast and diverse pool of potential patients for clinical trials. This is particularly true for endemic and neglected tropical diseases, making Africa an ethically imperative and scientifically valuable location for research that can yield globally significant results.3 This transforms a historical disadvantage into a strategic advantage, attracting trials that are highly relevant to its populations and contribute to global health solutions.

Existing infrastructure and expertise, particularly in infectious diseases, provide a strong foundation. Partnerships with organizations like the Africa Centres for Disease Control and Prevention (Africa CDC), the European and Developing Countries Clinical Trials Partnership (EDCTP), and the Regional Centres of Regulatory Excellence (RCOREs), along with the WHO's TDR network, have built substantial capacity.1 This has enabled pioneering research, such as the IMPALA trial evaluating long-acting antiretrovirals for HIV across seven sites in sub-Saharan Africa.1

The ongoing efforts towards regulatory harmonization, notably the operationalization of the African Medicines Agency (AMA) and the African Medicines Regulatory Harmonization (AMRH) initiatives, promise to accelerate approval timelines and strengthen regulatory processes.37 This creates a more predictable and streamlined environment for sponsors, fostering greater investment.

The rapid adoption and integration of digital health innovations, including AI, telemedicine, and personalized medicine, offer transformative potential. These technologies can address challenges related to access, efficiency, and cost, particularly in resource-limited settings, by enabling remote monitoring, optimizing data management, and improving diagnostic capabilities.44

Public-Private Partnerships (PPPs) are emerging as crucial mechanisms for mobilizing resources, driving innovation, and transforming healthcare delivery. By leveraging private sector efficiency and capital, PPPs can bridge critical funding and infrastructure gaps.46 Furthermore, a growing ecosystem of African health tech startups and innovators are developing contextually relevant and sustainable solutions, demonstrating the continent's capacity for homegrown innovation.22 Finally, ongoing capacity building initiatives, supported by organizations like EDCTP and GSK Africa Open Lab, are continuously investing in training and developing African researchers, further strengthening the continent's research capabilities.25

Table 2: Challenges and Opportunities in African Clinical Trial Funding

This table systematically outlines the financial challenges and opportunities within the African clinical trial landscape. It provides a clear comparative view of the hurdles related to funding, such as under-representation and reliance on external sources, alongside the diverse avenues for investment, including philanthropic, private sector, and governmental initiatives. This structure helps readers quickly grasp the complexities and potential solutions in the funding ecosystem, reinforcing the need for strategic financial interventions to bolster African health research.

3.3. Ethical Considerations and Best Practices in Community Engagement

Ethical conduct is a non-negotiable cornerstone of clinical trials, particularly in Africa where research participants may be vulnerable due to factors such as poverty, low education levels, and limited empowerment.57 All clinical trials conducted on the continent must rigorously adhere to international ethical principles, including those outlined in the World Medical Association Declaration of Helsinki and Good Clinical Practice (GCP) guidelines, in addition to complying with national and regional regulations.58 This commitment ensures the protection of participants' rights and well-being.

Informed Consent (IC) Challenges and Innovations:

A significant ethical and practical challenge in African clinical trials revolves around obtaining truly informed consent. Studies indicate that recall and understanding of informed consent information are often low, a problem exacerbated by increasingly lengthy and complex consent forms and generally lower health literacy levels among populations.59 The linguistic diversity across Africa presents a particularly acute barrier. In many parts of West Africa, for instance, numerous local languages are predominantly oral and lack written forms, making it difficult to adhere to international requirements for written consent in a language the participant can read and understand.31 Audits have revealed instances where participants signed consent forms in official languages like French or English despite limited comprehension, raising serious ethical concerns about the validity of such consent.31

To address these complexities, innovative strategies are being explored and implemented. These include simplifying written information, incorporating illustrations, altering document layouts to highlight critical points, and utilizing audio-visual presentations.60 One-on-one discussions with study team members have proven particularly effective in improving participants' understanding, especially for low-literacy populations.61 Furthermore, the use of culturally relevant metaphors can significantly enhance comprehension of complex scientific concepts, such as randomization in trials, by relating them to familiar everyday experiences.62 These adaptations demonstrate that ethical practice in Africa is not merely about compliance but about creative, context-specific approaches to foster genuine understanding and trust.

Community Engagement (CE) Best Practices:

Meaningful community engagement is paramount for the ethical and scientific quality, relevance, and ultimate acceptance of research within affected communities.57 It is crucial that community representatives are intimately involved from an early and sustained stage in the research lifecycle, including study design, development, implementation, and the dissemination of reliable data.57 Effective community engagement is facilitated by appropriate community entry strategies and consistent engagement with diverse stakeholders.63

However, barriers to effective CE can include prohibitive cultural, historical, or religious practices, geographical limitations, and difficulties in planning and executing engagement activities due to communication barriers.63 To overcome these, various practices are adopted, such as awareness creation and sensitization through local drama, social media, documentaries, and community durbars.63 Building trust and fostering a sense of ownership of the research endeavor among stakeholders, especially the host community, is considered ideal for ensuring the success and long-term sustainability of research projects.63 While gender mainstreaming is recognized as important in CE, it is often not adequately integrated throughout the research cycle, highlighting a need for more nuanced consideration of gender as a social construct.63

Research Ethics Committees (RECs) Challenges:

The integrity of ethical oversight relies heavily on the capacity of Research Ethics Committees. However, RECs in Africa frequently face challenges related to inadequate funding, staffing, and training.28 This can lead to a situation where committees, lacking sufficient expertise in ethical aspects, may inadvertently prioritize scientific or budgetary considerations over comprehensive ethical review.29 Concerns about the independence of RECs can also arise, particularly when approving research could lead to increased funding for their own institutions.29 Addressing these systemic vulnerabilities is critical for ensuring robust and impartial ethical review.

The need to tailor ethical practices to local realities, including innovative informed consent and robust community engagement, positions Africa to demonstrate ethical leadership in global health research. By adapting and innovating within its diverse, low-resource settings, Africa can develop and exemplify best practices for ethical research that are relevant globally, particularly for vulnerable populations worldwide. This approach moves beyond simply "protecting" research participants to genuinely "empowering" communities, fostering a more equitable and collaborative research environment.

4. Funding and Partnerships: Fueling Innovation through Clinical Trials

4.1. Diverse Funding Mechanisms and the Investment Landscape in Africa

The financial landscape for clinical trials and health innovation in Africa is characterized by a complex interplay of challenges and opportunities, with a notable reliance on external funding.

Challenges in Funding:

A primary challenge is the persistent under-investment in health research and development by African governments. Many nations consistently fall short of the African Union's agreed-upon target of allocating 1% of their Gross Domestic Product (GDP) to scientific research and innovation.34 This shortfall leads to a heavy dependence on external funding sources, which, while crucial, can create a precarious situation. Such reliance can lead to a research agenda that is heavily influenced by the priorities and directives of external partners, potentially misaligning with Africa's most pressing health needs or neglecting critical areas like non-communicable diseases (NCDs).64

Furthermore, the distribution of existing funding is often uneven. For instance, while cancer research funding in Africa is increasing, it remains concentrated in a few countries, leaving many others with limited resources.54 Specific cancers, such as cervical, prostate, and liver cancers, are also underfunded relative to their significant impact on the continent.54 The fragmented nature of investments often results in "transactional gains" that are not sustained over time, failing to build long-term, systemic capacity within the clinical trial ecosystem.36 Compounding these issues are broader financial constraints, including high public debt levels and recurrent budget cuts in many African nations, which limit their ability to allocate sufficient domestic funds to health research.53 This creates a dual challenge of both scarcity and sustainability in funding, where even when resources are available, their impact may be limited by short-term focus and lack of coordination.

Funding Sources and Opportunities:

Despite these challenges, diverse funding mechanisms are actively supporting clinical research in Africa. International and philanthropic organizations are major contributors. The European & Developing Countries Clinical Trials Partnership (EDCTP), for example, has invested hundreds of millions of Euros in collaborative clinical research and capacity building in sub-Saharan Africa, supporting numerous projects and fellowships.51 The UK's National Institute for Health and Care Research (NIHR) has significantly contributed to EDCTP programs, effectively doubling available funding for critical work like mpox research.51 The Bill & Melinda Gates Foundation is another key supporter, backing initiatives such as the Grand Challenges African Drug Discovery Accelerator.21

While domestic government funding remains a challenge, some countries are making notable efforts. Zimbabwe, for instance, has prioritized investments in primary healthcare and introduced "sin taxes" on products like cigarettes and energy drinks to fund relief from non-communicable diseases such as cancer and diabetes.53 This demonstrates innovative approaches to domestic resource mobilization.

The private sector, particularly venture capital (VC) and private equity, is showing increasing interest in the African health space. In Southern Africa, the health sector accounted for 20% of venture capital deal value in 2024, the highest since 2015, driven by renewed investor interest in life sciences, biotechnology, and medical devices.56 Venture capitalists are drawn by the rapid growth of the African healthcare market and the rising demand for services.23 Development Finance Institutions (DFIs) also play a crucial role; the International Finance Corporation (IFC) has invested and mobilized over $1.1 billion in the health and life sciences sectors in Africa over the last two decades, supporting private providers, pharmaceutical manufacturers, and innovative startups.55

To move towards a more equitable and self-reliant health research agenda, a significant increase in domestic, coordinated, and sustainable funding is essential. This requires not only innovative financing mechanisms but also a strategic approach to attracting and leveraging private sector and venture capital, ensuring that investments align with African health priorities and contribute to local economic growth and health equity.

4.2. The Transformative Role of Public-Private Partnerships (PPPs)

Public-Private Partnerships (PPPs) are emerging as crucial mechanisms for accelerating innovation and transforming healthcare delivery across Africa. These collaborative models are increasingly recognized as "pivotal levers" for mobilizing resources and driving advancements, particularly in critical areas like diagnostics and laboratory medicine.46 PPPs offer a strategic pathway to address significant public-sector deficits in efficiency, innovation, and capital by leveraging the expertise and financial backing of the private sector to build, maintain, and operate essential healthcare infrastructure.46

Beyond merely providing capital, PPPs are powerful drivers of technological innovation in healthcare. They facilitate the adoption of cutting-edge solutions such as AI-powered diagnostics, telemedicine platforms, and integrated electronic medical records.46 This collaborative approach fosters a vibrant ecosystem for health tech startups, enabling them to scale their innovations and reach wider populations. A notable example is the "Investing in Innovation (i3) Africa" program, which has provided $50,000 grants to 60 promising African health tech startups. In just two years, this program has catalyzed over 70 partnerships, created more than 700 jobs, and impacted approximately 190 million patient visits annually.49 Such initiatives demonstrate that well-structured PPPs can directly translate investment into tangible health outcomes and job creation, effectively bridging the gap between innovation and real-world impact.

Furthermore, PPPs play a vital role in human capital development. Through structured knowledge exchange, technical training, and partnerships with academic institutions, they contribute to the upskilling of healthcare professionals and enhance institutional capacity.46 This ensures that local professionals are not only trained in new systems and equipment but are also equipped to drive and sustain change within their health systems. PPPs are therefore essential for creating a vibrant, self-sustaining health innovation ecosystem in Africa. They enable the scaling of local innovations that are contextually relevant and address specific community needs, moving beyond a reliance on imported solutions and fostering greater self-reliance in healthcare.

5. African-Led Innovations and Success Stories

Africa is increasingly becoming a hotbed of innovation, with numerous groundbreaking solutions emerging from clinical trials and local entrepreneurial efforts. These African-led innovations are often tailored to address the continent's unique challenges, demonstrating ingenuity in resource-constrained environments and offering valuable lessons for global health.

5.1. Pioneering Medical Device Innovations from Clinical Trials

Medical device clinical trials (MDCTs) are crucial for generating the performance data on safety, efficacy, and efficiency required before new devices can be commercialized.20 While the growth of MDCTs in Africa has been slower compared to other regions, with trials concentrated in a few countries like Egypt, South Africa, Uganda, Kenya, Tanzania, and Nigeria, they are actively addressing a wide spectrum of healthcare challenges, including infectious diseases, non-communicable diseases (NCDs), and nutritional disorders.20

African innovators are developing highly contextualized medical devices that leverage available resources and address specific local needs. Notable examples include:

• Crib A'Glow (Nigeria): This portable, solar-powered phototherapy crib was designed to treat neonatal jaundice, a common affliction exacerbated by a lack of phototherapy units and unreliable electricity in many rural areas. This innovation has successfully treated over 600 babies, demonstrating a practical solution to a critical maternal and child health issue.48

• DREET (Botswana): A mobile phone-based hearing test that can be administered in just four minutes. Its design allows for use by individuals who cannot read or write, including very young children, making it highly accessible in diverse communities.48

• Non-pneumatic Anti-Shock Garment (NASG): This first-aid device, developed to address postpartum hemorrhage, has undergone trials in Zimbabwe and Zambia, offering a vital tool for maternal health in low-resource settings.20

• ShangRing device for circumcision and UniCirc: These devices have been part of clinical trials aimed at improving male circumcision procedures, which are relevant for HIV prevention efforts.20

• CRADLE vital signs device: This innovation focuses on monitoring vital signs, crucial for patient management in various clinical contexts.20

• Urine-based Xpert MTB/RIF: A diagnostic tool for HIV/TB, demonstrating advancements in rapid and accessible diagnostics.20

• 3D Printing: In Kenya, Ultra Red Technologies exemplifies local ingenuity by utilizing 3D printing to produce essential medical supplies, such as face masks and ventilator components, addressing shortages and supply chain challenges.45

• Drone Technology: Companies like Zipline and LifeBank are employing drones to deliver critical medical supplies, including blood and oxygen, directly to remote areas, effectively circumventing traditional logistical hurdles.45

• Ilara Health (Kenya): This company uses artificial intelligence (AI) to detect respiratory illnesses by analyzing cough sounds, showcasing a low-cost, high-impact diagnostic innovation.45

• African Medicines Innovations and Technology Development Platform (AMITD) in South Africa: This platform is dedicated to research and development in traditional herbal medicines, drug discovery, and conducting clinical trials of herbal products, tapping into indigenous knowledge for health solutions.66

These examples highlight a significant trend in African innovation: a focus on "frugal innovation" and "leapfrogging" older technologies. Instead of replicating established, often capital-intensive Western models, African innovators are directly adopting and adapting cutting-edge solutions like mobile technology, AI, and drones to solve immediate, pressing healthcare needs. This approach not only addresses local challenges effectively but also generates novel solutions that hold global relevance, particularly for other low- and middle-income countries. African-led medical device innovation is thus not merely catching up; it is actively shaping a new paradigm for efficient, accessible, and contextually relevant healthcare technology, offering valuable lessons and models for global health.

5.2. Advancements in Pharmaceutical Product Development and Health Tech Startups

African clinical trials are not only validating existing treatments but are also serving as crucial platforms for the development of new pharmaceutical products and the growth of innovative health tech startups, marking a significant shift in the continent's role in global health.

Pharmaceutical Product Development:

Ghana's Drug Innovation Group (DIG) at the University of Ghana is at the forefront of this movement. Since 2016, DIG has been leading a research network in medicinal chemistry, dedicated to discovering new treatments for malaria, tuberculosis (TB), and cancer.21 This initiative is part of the broader Grand Challenges African Drug Discovery Accelerator (GC ADDA), a US$4.7 million program supported by the Bill & Melinda Gates Foundation and LifeArc, which fosters a continent-wide network of scientists. A notable success story involves the

Drugs for Neglected Diseases initiative (DNDi), which has delivered 13 treatments for vulnerable populations over two decades. DNDi often takes promising compounds abandoned by large pharmaceutical companies for commercial reasons, such as fexinidazole, a sleeping sickness treatment originally developed in the 1980s. After years of development and clinical trials, fexinidazole began treating patients in the Democratic Republic of the Congo in 2019, significantly reducing sleeping sickness incidence.21

The Aurum Institute continues to contribute significantly to pharmaceutical innovation, conducting trials for TB treatment and prevention, including studies on promising alternatives to high-toxicity drugs, with results expected in July 2025.18 Their work includes a partnership with Gilead for HIV prevention research. Similarly, the

GSK Africa Open Lab has committed £10 million (2022-2027) to fund research projects and strengthen research capabilities in sub-Saharan Africa, with a focus on high-burden infectious diseases like malaria, TB, and drug-resistant bacterial infections.25 The

Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa) in Ethiopia also plays a vital role, hosting clinical trials for infectious diseases like TB and leishmaniasis, as well as non-communicable diseases such as schizophrenia.26

Health Tech Startups:

Africa's health tech startup scene is burgeoning, with companies leveraging advanced technologies to address healthcare gaps and drive innovation:

• Yemaachi Biotech (Ghana): This company utilizes immunogenomics, bioinformatics, and AI for advanced cancer detection and treatment. Their aim is to reduce the economic burden of cancer on patients and expand access to precision oncology tools through a dedicated clinical trial network.22

• 54Gene (Nigeria): A critical player in addressing the significant gap in genomic data representation for African populations, which currently accounts for less than 3% of global datasets. 54Gene provides precision medicine solutions, molecular diagnostics, and genetic testing. The company has partnered with major global pharmaceutical companies and the African Union Development Agency (AUDA-NEPAD) to establish a genomics research center and a biobank initiative, ensuring that future medications are developed with diverse populations in mind.22

• PBR Life Sciences (Kenya/Ghana): This startup employs AI for data standardization to meet WHO requirements, actively building what is anticipated to be the "largest anonymized dataset of Black patients in the world" to boost clinical research. This initiative is crucial for ensuring that future drug discovery and development adequately consider African genetic diversity.24

• Viebeg (Rwanda): Leveraging AI, Viebeg has significantly improved medical supply procurement and equipment financing for health facilities, leading to substantial cost reductions and improved stock-outs. This innovation directly impacts the accessibility and efficiency of healthcare delivery.67

These examples collectively demonstrate a profound transformation in Africa's role in global health. The continent is shifting from being primarily a recipient of global health interventions to becoming a significant producer and innovator of health solutions. This proactive engagement, particularly in genomics and AI-powered diagnostics, directly addresses the historical under-representation of African populations in research, ensuring that future medical advancements are more equitably designed and effective worldwide. This trend not only improves health outcomes on the continent but also fosters economic growth, creates high-value jobs, and firmly establishes Africa as a vital contributor to global scientific knowledge and pharmaceutical development, moving towards greater scientific and health sovereignty.

Table 3: Summary of African-Led Healthcare Innovations from Clinical Trials

This table highlights specific and tangible examples of healthcare innovations that have originated from or been significantly developed in Africa, often through the direct or indirect leveraging of clinical research. It provides concrete evidence of the continent's growing innovative capacity across medical devices, pharmaceuticals, and digital health. By showcasing the key impact or outcome of each innovation, the table reinforces the practical benefits of investing in and fostering local clinical research and entrepreneurship.

6. Policy and Regulatory Frameworks for a Robust Innovation Ecosystem

6.1. The African Medicines Agency (AMA) and Regulatory Harmonization Efforts

The establishment and operationalization of the African Medicines Agency (AMA) represent a monumental stride towards strengthening Africa's health innovation ecosystem. Formally established in 2019 and operational as of July 2025 with its headquarters in Kigali, Rwanda, AMA is a Specialized Agency of the African Union (AU).37 Its primary vision is to ensure "African People have Access to essential Medical Products and Technologies".38

Mandate and Functions: AMA's comprehensive mandate includes providing oversight on the quality, safety, and efficacy of medicines and health products across Africa.37 It aims to bolster national regulatory systems by offering technical assistance, training, and capacity-building initiatives, thereby harmonizing regulatory practices across member states to create a more streamlined and efficient process.37 Crucially, AMA will coordinate joint reviews of clinical trial applications for vaccines and "highly complex" product dossiers, such as biosimilars.38 It will also conduct regular inspections of Active Pharmaceutical Ingredient (API) manufacturing sites and play a critical role in combating substandard and falsified medical products, which pose a significant threat to public health and economies.38

African Medicines Regulatory Harmonization (AMRH) Initiative: AMA builds upon the foundations laid by the African Medicines Regulatory Harmonization (AMRH) initiative, which commenced in 2009 to address the continent's weak, outdated, and fragmented regulatory systems.43 The AMRH initiative has achieved significant progress, including full regional regulatory harmonization with the inclusion of North Africa in February 2025.40 This milestone brings Africa considerably closer to continental harmonization. A landmark agreement among leading National Medicines Regulatory Authorities (NRAs) further fosters collaboration and streamlines processes through information sharing, work-sharing, and reliance on regulatory decisions, aiming to expedite approvals and reduce costs.39

African Vaccine Regulatory Forum (AVAREF): Complementing these efforts, the African Vaccine Regulatory Forum (AVAREF), established by the World Health Organization (WHO) in 2006, has played a pivotal role in strengthening clinical trial regulation. Its mandate expanded in 2018-2020 to cover all medical products, not just vaccines. AVAREF has developed standardized templates for clinical trial applications and Good Clinical Practice (GCP) inspections, with the ambitious goal of achieving a 60-working-day timeline for review and approval or rejection of clinical trials.27

Challenges to Full Implementation: Despite this remarkable progress, the full implementation of AMA and the broader regulatory harmonization agenda faces ongoing challenges. These include varying levels of political commitment among member states, differences in risk-benefit interpretation, and the persistence of weak legal and regulatory frameworks in some countries.69 Inadequate financial mechanisms and a lack of competent regulatory professionals, coupled with high staff turnover, also impede progress.70 The implementation targets for the AU Model Law have not been fully met across all nations.70

The operationalization of AMA and the progress in regulatory harmonization are crucial for attracting investment and ensuring access to innovative medicines. A harmonized and predictable regulatory environment significantly reduces the administrative burden and costs for sponsors, making Africa a more attractive destination for clinical trial investment.3 This, in turn, accelerates the approval and availability of new medicines and health products on the continent, directly addressing the critical access gap. Furthermore, the concerted effort to combat substandard and falsified medical products builds essential public trust, which is vital for both trial participation and the widespread adoption of new health technologies. Effective regulatory harmonization is not merely a bureaucratic improvement; it is a strategic economic and public health tool that integrates African markets, enhances their global competitiveness, and ensures that innovations reach patients safely and quickly.

6.2. Strategic Initiatives and Policy Recommendations from Continental Bodies (AU, Africa CDC, WHO AFRO, AAS)

Continental bodies are actively developing and implementing strategic initiatives to cultivate a robust and self-reliant health innovation ecosystem in Africa, with a strong emphasis on leveraging clinical trials.

African Union (AU) and Africa Centres for Disease Control and Prevention (Africa CDC):

The AU's "Africa Health Strategy 2016-2030" advocates for locally driven and financed research, encouraging member states to establish innovative hubs and allocate 1% of their GDP to research and innovation.64 However, many countries are yet to meet this target.64 To address fragmentation and enhance coordination, Africa CDC and AUDA-NEPAD convened experts in May 2023 to develop concrete solutions for strengthening the African clinical trials ecosystem. This meeting proposed a coordination mechanism, to be housed at Africa CDC in partnership with AUDA-NEPAD, WHO AFRO, and AVAREF, aimed at fostering collaboration, strengthening the workforce, streamlining systems, and harmonizing ethics and regulatory reviews.36 This initiative reflects a conscious effort to move towards a more cohesive, integrated, and impactful research landscape.

A new Memorandum of Understanding (MoU) signed in February 2025 between Africa CDC and Global Health EDCTP3 further reinforces this commitment. The MoU outlines a structured Joint Action Plan (2025-2027) focused on strengthening the public health workforce, enhancing clinical trial ecosystems, advancing clinical development of interventions against infectious diseases, supporting capacity building for local manufacturing of health products, and enabling equitable partnerships.71 Africa CDC also champions a standardized approach to health research prioritization, African-centered ethics that respect cultural values, and a continental governance framework to harmonize research efforts.64 A capacity mapping initiative is underway to comprehensively assess research capabilities across member states, with the findings expected to be pivotal for strengthening continental research capacity.64 Plans are also in motion to launch a regional scientific advisory group and a continental ethics review committee in 2025.64

World Health Organization Regional Office for Africa (WHO AFRO):

The WHO Innovation Hub, with its vision to drive health equity, accessibility, and positive health outcomes through innovation (especially digital health), plays a supportive role. Its strategic pillars include ecosystem building, innovation scale-up, and normative guidance.72 WHO AFRO's "Research for Health: A strategy for the African region, 2016-2025" directly addresses the continent's double burden of communicable and non-communicable diseases and health system challenges.73 WHO AFRO also actively develops normative guidance, ethics tools, and capacity-building programs for Research Ethics Committees, emphasizing community involvement in research design and data dissemination to ensure ethical and scientific quality.57

African Academy of Sciences (AAS):

The AAS is a key advocate for leveraging Science, Technology, and Innovation (STI) for sustainable development in Africa. Its Strategic Plan (2023-2027) focuses on health and well-being, aiming to increase clinical trial investments by enhancing the visibility of African trialists and sites, and promoting transparent regulatory and ethics procedures.74 The Advancing Capacity for Early Phase Trials for Pandemics and Epidemics in Africa (ACCEPT-Africa) Consortium, an AAS affiliate, exemplifies this commitment by strengthening Africa's response to epidemic-prone diseases through clinical trial networks and capacity building in areas like pharmacokinetics, trial design, and bioethics.77

These policy initiatives are crucial for Africa to gain greater strategic autonomy in its health research agenda. By coordinating efforts, building local capacity, and setting its own priorities, Africa can ensure that clinical trials and innovation pathways serve its unique needs, ultimately contributing to a more equitable global health landscape. The emphasis on a coordinated, Africa-led research agenda is a direct response to the identified challenge of fragmented, transactional investments, aiming to optimize resource allocation and ensure that research outputs translate into meaningful health outcomes for African populations.

7. Conclusion

Clinical trials are undeniably indispensable for driving healthcare innovation globally, and their strategic leveraging is rapidly transforming the landscape of creativity and entrepreneurship across Africa's medical and healthcare sectors. The analysis presented in this paper underscores a dynamic evolution, where traditional validation processes are giving way to technologically advanced, patient-centric, and data-driven research environments. Digital tools, artificial intelligence, and wearable devices are not merely enhancing efficiency but are fundamentally reshaping how clinical trials are designed, conducted, and analyzed, enabling greater precision, accessibility, and speed in drug discovery and development.

Despite this transformative potential, Africa faces a critical paradox: a quarter of the global disease burden is borne by the continent, yet it remains severely underrepresented in global clinical trials. This disparity results in a significant lack of tailored interventions for African populations and impedes the continent's access to cutting-edge medical advancements. However, this challenge is simultaneously a profound opportunity. Africa boasts a maturing clinical trial infrastructure, a growing network of highly skilled researchers, and a burgeoning ecosystem of African-led innovations in pharmaceuticals, medical devices, and digital health. These homegrown solutions, often characterized by frugal innovation and the strategic adoption of leapfrogging technologies, are demonstrating remarkable contextual relevance and global applicability.

Significant progress is being made in establishing robust policy and regulatory frameworks. The operationalization of the African Medicines Agency (AMA) and the ongoing African Medicines Regulatory Harmonization (AMRH) initiatives are pivotal steps towards streamlining regulatory processes, enhancing safety oversight, and creating a more attractive environment for clinical trial investment. Concurrently, continental bodies like the African Union, Africa CDC, WHO AFRO, and the African Academy of Sciences are actively developing strategic initiatives to foster a coordinated, Africa-led research agenda, emphasizing capacity building, local manufacturing, and equitable partnerships.

Nevertheless, persistent challenges remain, particularly concerning sustainable domestic funding, the uneven distribution of investments, and the need for consistent capacity and independence across Research Ethics Committees. Ethical considerations, especially around informed consent in diverse linguistic and cultural contexts, require continuous innovation and culturally sensitive approaches to ensure genuine participant understanding and trust.

Ultimately, the trajectory of innovation pathways in African healthcare is moving towards a future where the continent is not merely a recipient of global health solutions but a significant and sovereign contributor to the global health and scientific landscape. By strategically addressing the remaining gaps in funding, regulatory consistency, and ethical implementation, Africa can fully unlock its immense potential, drive equitable access to health innovations, and solidify its position as a vital hub for medical advancement that benefits both its own populations and the wider world.

8. Recommendations for Future Action and Policy

To fully leverage clinical trials for innovation, creativity, and entrepreneurship in the African medical and healthcare sectors, a concerted and multi-faceted approach involving all stakeholders is essential. The following recommendations outline key areas for future action and policy development:

8.1. Bolstering Domestic Investment and Sustainable Financing

African governments must demonstrate stronger political commitment by significantly increasing domestic investment in health research and development (R&D). This includes striving to achieve, and ideally exceed, the African Union's target of allocating 1% of GDP to R&D.64 Innovative domestic financing mechanisms, such as dedicated health innovation funds, "sin taxes" on unhealthy products, or public health levies, should be explored and implemented to create sustainable funding streams.53

• Rationale: Over-reliance on external funding can create dependency and potentially misalign research priorities with local needs.64 Sustainable domestic funding ensures African ownership of the health agenda, fosters long-term capacity building, and moves beyond short-term "transactional gains" from project-specific external investments.36 It also signals commitment to international partners, encouraging co-investment.

8.2. Accelerating Regulatory Harmonization and Capacity Building

Member states should expedite the full ratification and implementation of the African Medicines Agency (AMA) Treaty and actively participate in African Medicines Regulatory Harmonization (AMRH) initiatives.37 This will streamline regulatory processes, reduce administrative burdens for clinical trial sponsors, and ensure consistent standards across the continent.3 Concurrent investment is crucial for strengthening National Regulatory Authorities (NRAs) and Research Ethics Committees (RECs) through targeted training programs, increased staffing, and improved financial autonomy.28

• Rationale: A harmonized, predictable, and efficient regulatory environment is a powerful magnet for clinical trial investments, accelerating access to safe and effective medical products for African populations.3 Strong, independent, and well-resourced RECs are indispensable for robust ethical oversight and maintaining public trust in research.57

8.3. Fostering Patient-Centric and Culturally Sensitive Clinical Trial Design

Clinical trial sponsors and researchers must prioritize patient-centric design and implement innovative informed consent (IC) strategies tailored to local linguistic and cultural contexts. This includes developing simplified consent forms, utilizing audio-visual aids, incorporating illustrations, and conducting extensive one-on-one discussions to ensure genuine comprehension, especially for low-literacy populations.31 Community engagement should be initiated early and sustained throughout the research lifecycle, involving community representatives in study design, implementation, and dissemination of findings.57

• Rationale: Authentic informed consent is a fundamental ethical imperative that upholds participant autonomy.31 Culturally sensitive and participatory approaches build trust, enhance recruitment and retention rates, and ensure that research is relevant and acceptable to the communities it aims to serve, leading to more robust and impactful scientific outcomes.63

8.4. Promoting Public-Private Partnerships and Local Entrepreneurship

Governments, international development partners, and philanthropic organizations should actively support and scale successful Public-Private Partnership (PPP) models, such as the "Investing in Innovation (i3) Africa" program, that effectively connect local health tech startups with funding, mentorship, and global market access.49 Policies should incentivize private sector investment in African-led health innovations, particularly in neglected disease areas and the growing burden of non-communicable diseases, where market solutions are urgently needed.1

• Rationale: PPPs are crucial for mobilizing private sector efficiency, capital, and technological innovation, bridging critical gaps in healthcare infrastructure and service delivery.46 Supporting local entrepreneurship ensures that health solutions are contextually relevant, sustainable, and contribute directly to local economic development and job creation, fostering a self-reliant innovation ecosystem.49

8.5. Leveraging Digital Health and AI for Accelerated Innovation

Significant investment is required in digital infrastructure across Africa, including reliable internet connectivity and digital literacy programs, to fully harness the potential of AI, telemedicine, and data science in healthcare.8 Development of secure, interoperable, and anonymized pan-African health data platforms is critical to support advanced analytics, drug discovery, and precision medicine tailored to the continent's diverse populations.24

• Rationale: Digital technologies and AI offer unparalleled opportunities for enhancing the efficiency, precision, and accessibility of clinical trials and healthcare delivery, particularly in resource-constrained and geographically dispersed settings.7 Addressing the historical data gap for African populations is fundamental to developing globally relevant and equitably designed future medical interventions.24

8.6. Strengthening Continental Coordination and Research Prioritization

The Africa CDC's proposed coordination mechanism for the African clinical trials ecosystem should be fully operationalized and empowered to align research priorities with the continent's actual disease burden and public health needs.36 This mechanism should foster robust pan-African research networks, reduce fragmentation, and ensure that research investments translate into tangible health outcomes for African populations. The planned regional scientific advisory group and continental ethics review committee will be vital components of this coordinated effort.64

• Rationale: Coordinated efforts are essential to optimize resource allocation, prevent duplication, and ensure that research outputs are effectively translated into public health interventions.36 This strategic alignment is crucial for Africa to drive its own health research agenda and maximize its contribution to global health security.

References

African Academy of Sciences. (2024, September). AAS Brochure - Final September 2024. https://portal.aasciences.app/storage/publications/24092024014903AAS%20Brochure%20-%20Final%20September%202024.pdf 76

Africa CDC. (n.d.). Journal of Public Health in Africa. Retrieved from https://africacdc.org/journal-of-public-health-in-africa/ 79

Africa CDC. (n.d.). Landmark agreement among Africa’s leading national medicines regulatory authorities to foster collaboration. Retrieved from https://africacdc.org/news-item/landmark-agreement-among-africas-leading-national-medicines-regulatory-authorities-to-foster-collaboration/ 39

Africa CDC. (2023, May). Meeting Report: Optimizing Efficiency and Impact in the African Clinical Trials Ecosystem. https://africacdc.org/download/meeting-report-optimizing-efficiency-and-impact-in-the-african-clinical-trials-ecosystem/ 36

Africa CDC. (2024, November 21). The African health research agenda should focus on delivering more health outcomes. Retrieved from https://africacdc.org/news-item/the-african-health-research-agenda-should-focus-on-delivering-more-health-outcomes/ 64

Africa Pandemic Sciences Collaborative. (n.d.). Clinical Research and Trials. Retrieved from https://www.africapandemicsciences.org/clinical-research-and-trials 77

African Development Bank. (n.d.). How Rwanda is using artificial intelligence to improve healthcare. Retrieved from https://www.afdb.org/en/success-stories/how-rwanda-using-artificial-intelligence-improve-healthcare-55309 67

African Medicines Agency. (n.d.). African Medicines Agency (AMA). Clinical Trials Community Africa. Retrieved from https://www.ctc.africa/ama 37

African Union. (2025, June 2). African Medicines Agency (AMA) to Hold Second Ordinary Session of Conference of State Parties. Retrieved from https://au.int/en/newsevents/20250602/african-medicines-agency-ama-hold-second-ordinary-session-conference-state 42

African Academy of Sciences. (n.d.). The Clinical Trials Community. YouTube. Retrieved from https://www.youtube.com/watch?v=RQpag947fcc 74

The Aurum Institute. (n.d.). Clinical Research. Retrieved from https://www.auruminstitute.org/what-we-do/what-we-do/clinical-research 18

AUDA-NEPAD. (n.d.). Africa Achieves Full Regional Regulatory Harmonization, Marking a new chapter of same medicine standards across the continent. Retrieved from https://www.nepad.org/news/africa-achieves-full-regional-regulatory-harmonization-marking-new-chapter-of-same 40

AUDA-NEPAD. (n.d.). African Medicines Regulatory Harmonization (AMRH) programme. Retrieved from https://amrh.nepad.org/ 43

AstraZeneca. (n.d.). Clinical innovation. Retrieved from https://www.astrazeneca.com/r-d/clinical-innovation.html 7

BMC Medical Ethics. (2018, December 20). Improving informed consent in a low-income setting: a randomized trial of an audio-visual intervention for the BabyGel study in rural eastern Uganda. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6304001/ 60

Brookings. (n.d.). Health care in Africa: Emerging technologies at play. Retrieved from https://www.brookings.edu/articles/health-care-in-africa-emerging-technologies-at-play/ 45

Desmond Tutu Health Foundation. (n.d.). FAQs. Retrieved from https://desmondtutuhealthfoundation.org.za/faqs/ 15

DIA Global Forum. (2025, April). Informed consent in West Africa: Bridging regulatory compliance and cultural diversity. Retrieved from https://globalforum.diaglobal.org/issue/april-2025/informed-consent-in-west-africa-bridging-regulatory-compliance-and-cultural-diversity/ 31

EDCTP. (n.d.). Ethics & Regulatory Affairs. Retrieved from http://www.edctp.org/ethics-regulatory-affairs/ 58

Forbes Africa. (2025, July 24). Tech And Health Industries Contribute Billions To South Africa's VC Sector, Report Finds. Retrieved from https://www.forbesafrica.com/current-affairs/2025/07/24/tech-and-health-industries-contribute-billions-to-south-africas-vc-sector-report-finds/ 56

Frontiers. (2025). Digital Health Innovations in Africa: Harnessing AI, Telemedicine, and Personalized Medicine for Improved Healthcare. Retrieved from https://www.frontiersin.org/research-topics/62391/digital-health-innovations-in-africa-harnessing-ai-telemedicine-and-personalized-medicine-for-improved-healthcare 44

Gavi. (2025, July 24). Medicines for Africa: with cutting-edge research, Ghana leads the way. Retrieved from https://www.gavi.org/vaccineswork/medicines-for-africa-with-cutting-edge-research-ghana-leads-way 21

Global Health EDCTP3. (2025, February 17). Africa CDC and Global Health EDCTP3 sign Memorandum of Understanding to promote public health in Africa. Retrieved from https://www.global-health-edctp3.europa.eu/news-and-events/news/africa-cdc-and-global-health-edctp3-sign-memorandum-understanding-promote-public-health-africa-2025-02-17_en 71

Google. (2025, April 29). The Kenyan startup using AI to close data gaps in healthcare. Retrieved from https://blog.google/intl/en-africa/company-news/outreach-and-initiatives/the-kenyan-startup-using-ai-to-close-data-gaps-in-healthcare/ 24

GSK. (n.d.). Africa Open Lab. Retrieved from https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/africa-open-lab/ 25

IAVI. (n.d.). Africa Clinical Research Center Partners. Retrieved from https://www.iavi.org/africa/africa-clinical-research-centers/ 9

Jaza Rift. (n.d.). Venture Capitalists Flock to African Healthcare Space. Retrieved from https://jazarift.com/venture-capitalists-flock-to-african-healthcare-space/ 23

Journal of the National Cancer Institute. (2017, March 1). The effectiveness of metaphors for explaining randomization in clinical trials: A randomized trial. Retrieved from https://academic.oup.com/jnci/article/109/3/djw233/2905672 62

Kass, N. E., Hyder, A. A., & Johns Hopkins School of Public Health and Johns Hopkins Berman Institute of Bioethics. (2007, January 23). Report: Research Ethics Committees in Africa Face Challenges. Innovations Report. Retrieved from https://www.innovations-report.com/education/studies-and-analyses/report-77339/ 29

Kenya Medical Research Institute. (n.d.). African Journal of Health Sciences. Retrieved from https://www.kemri.go.ke/african-journal-of-health-sciences/ 81

Kenya Medical Research Institute. (n.d.). Centre for Clinical Research (CCR) - Nairobi. Retrieved from https://www.kemri.go.ke/centre-for-clinical-research-ccr-nairobi/ 11

Kenya Medical Research Institute. (n.d.). KEMRI Hosts Groundbreaking AI/ML Workshop to Power the Future of Drug Discovery in Africa. Retrieved from https://www.kemri.go.ke/kemri-hosts-groundbreaking-ai-ml-workshop-to-power-the-future-of-drug-discovery-in-africa/ 14

Lifebit. (n.d.). Clinical Research Technology: How Innovation is Shaping Clinical Trials. Retrieved from https://lifebit.ai/blog/clinical-research-technology/ 8

Matovu, A., Nakiyingi-Miiro, J., Kajumbula, H., & Nsubuga, R. N. (2024). A compound analysis of medical device clinical trials registered in Africa on clinicaltrials.gov. Trials, 25(1), 658. https://doi.org/10.1186/s13063-024-08470-4 20

NEPAD. (n.d.). African Medicines Agency (AMA). Retrieved from https://www.nepad.org/microsite/african-medicines-agency-ama 38

NIHR. (2025, May 20). Strengthening clinical trial capabilities and epidemic preparedness in Africa. Retrieved from https://www.nihr.ac.uk/blog/strengthening-clinical-trial-capabilities-and-epidemic-preparedness-africa 51

Pan African Medical Journal. (n.d.). About the Journal. ScienceOpen. Retrieved from https://www.scienceopen.com/collection/dbf2a419-69ec-479b-b8a7-682e2a59b522 82

PLOS One. (2020, August 13). Informed consent approaches for clinical trial participation of children of minor parents in sub-Saharan Africa: A systematic review. Retrieved from https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237088 30

ResearchGate. (2011, January). Improving the Informed Consent Process for Research Subjects with Low Literacy: A Systematic Review. Retrieved from https://www.researchgate.net/publication/229064917_Improving_the_Informed_Consent_Process_for_Research_Subjects_with_Low_Literacy_A_Systematic_Review 61

ResearchGate. (2022, November). Community engagement in research in Sub Saharan Africa: current practices, barriers, facilitators, ethical considerations and the role of gender - a systematic review. Retrieved from https://www.researchgate.net/publication/365775067_Community_engagement_in_research_in_Sub_Saharan_Africa_current_practices_barriers_facilitators_ethical_considerations_and_the_role_of_gender_-_a_systematic_review 63

SAA. (2025, July 15). Africa Medicines Agency: No longer a vision but a vital reality. Retrieved from https://www.saafrica.org/pages/2025/07/15/africa-medicines-agency-no-longer-a-vision-but-a-vital-reality/ 41

SciSpot. (n.d.). Top 8 Biotech Startups Creating Waves in Africa in 2025. Retrieved from https://www.scispot.com/blog/biotech-startups-creating-waves-in-africa 22

South African Journal of Bioethics and Law. (2022). Informed consent in clinical trials. Retrieved from https://samajournals.co.za/index.php/sajbl/article/view/301 59

The Cable. (2025, July 24). Public-private partnerships: Unlocking new opportunities in West African healthcare. Retrieved from https://www.thecable.ng/public-private-partnerships-unlocking-new-opportunities-in-west-african-healthcare/ 46

U.S. Department of Health and Human Services. (2024, June). International Compilation of Human Research Standards. 2024 Edition. Africa. https://www.hhs.gov/sites/default/files/ohrp-international-compilation-africa-2024.pdf 83

World Economic Forum. (2025, July 9). Improving access to innovative medicines in Africa starts with clinical trials. Retrieved from https://www.weforum.org/stories/2025/07/healthcare-access-africa-clinical-trials/ 1

World Health Organization. (2018, December). Harmonized tools for clinical trial regulation in Africa are imminent. DIA Global Forum. Retrieved from https://globalforum.diaglobal.org/issue/december-2018/harmonized-tools-for-clinical-trial-regulation-in-africa-are-imminent/ 27

World Health Organization. (n.d.). WHO Innovation Hub. Retrieved from https://www.who.int/teams/digital-health-and-innovation/who-innovation-hub 72

World Health Organization Regional Office for Africa. (n.d.). Ethics. Retrieved from https://www.afro.who.int/health-topics/ethics 57

World Health Organization Regional Office for Africa. (n.d.). Research for health: A strategy for the African region, 2016-2025. Retrieved from https://www.afro.who.int/publications/research-health-strategy-african-region-2016-2025 73

YouTube. (2025, March 19). Community engagement in clinical trials: ethics and best practices in Africa. Retrieved from https://www.youtube.com/watch?v=UqHBg5Sxhbw 78

Works cited

1. Improving access to innovative medicines in Africa starts with clinical trials, accessed July 25, 2025, https://www.gavi.org/vaccineswork/improving-access-innovative-medicines-africa-starts-clinical-trials

2. Clinical trials are key to improving medicines access in Africa - The World Economic Forum, accessed July 25, 2025, https://www.weforum.org/stories/2025/07/healthcare-access-africa-clinical-trials/

3. Partnerships and Collaborations: The Right Alliances for Clinical Trials in Africa | JCO Global Oncology - ASCO Publications, accessed July 25, 2025, https://ascopubs.org/doi/10.1200/JGO.19.00194

4. Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic | Clinical Infectious Diseases | Oxford Academic, accessed July 25, 2025, https://academic.oup.com/cid/article/80/Supplement_1/S9/8210484

5. Clinical Trials & Evidence Generation - Innovation Pathway, accessed July 25, 2025, https://innovationpathway.healthinnovationnenc.org.uk/pathway/evaluation/clinical-trials-and-evidence-generation/

6. Importance of clinical trials and contributions to contemporary medicine: commentary - PMC, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11721763/

7. Our approach to clinical innovation - AstraZeneca, accessed July 25, 2025, https://www.astrazeneca.com/r-d/clinical-innovation.html

8. Clinical Research Technology: 10 Powerful Innovations in 2025 - Lifebit, accessed July 25, 2025, https://lifebit.ai/blog/clinical-research-technology/

9. Africa Clinical Research Center Partners - IAVI, accessed July 25, 2025, https://www.iavi.org/africa/africa-clinical-research-centers/

10. ACE Research - A leading Africa Contract Research Organization (CRO), accessed July 25, 2025, https://aceresearchafrica.com/

11. CENTRE FOR CLINICAL RESEARCH (CCR) NAIROBI - KEMRI, accessed July 25, 2025, https://www.kemri.go.ke/centre-for-clinical-research-ccr-nairobi/

12. Kenya Medical Research Institute (KEMRI), accessed July 25, 2025, https://www.kemri.go.ke/

13. Kenya Medical Research Institute - Wikipedia, accessed July 25, 2025, https://en.wikipedia.org/wiki/Kenya_Medical_Research_Institute

14. KEMRI Hosts Groundbreaking AI/ML Workshop to Power the Future ..., accessed July 25, 2025, https://www.kemri.go.ke/kemri-hosts-groundbreaking-ai-ml-workshop-to-power-the-future-of-drug-discovery-in-africa/

15. FAQs - Desmond Tutu Health Foundation, accessed July 25, 2025, https://desmondtutuhealthfoundation.org.za/faqs/

16. Desmond Tutu Health Foundation Careers: Home, accessed July 25, 2025, https://desmondtutuhealthfoundationjobs.mcidirecthire.com/

17. Desmond Tutu Health Foundation: Home, accessed July 25, 2025, https://desmondtutuhealthfoundation.org.za/

18. Clinical Research - The Aurum Institute, accessed July 25, 2025, https://www.auruminstitute.org/what-we-do/what-we-do/clinical-research

19. The Aurum Institute - A Leading Health Impact Organisation - The Aurum Institute, accessed July 25, 2025, https://www.auruminstitute.org/

20. A compound analysis of medical device clinical trials registered in ..., accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11453074/

21. Medicines for Africa: with cutting-edge research, Ghana is at the forefront, accessed July 25, 2025, https://www.gavi.org/vaccineswork/medicines-for-africa-with-cutting-edge-research-ghana-leads-way

22. Top 8 Biotech Startups Creating Waves in Africa in 2025 | - Scispot, accessed July 25, 2025, https://www.scispot.com/blog/biotech-startups-creating-waves-in-africa

23. Venture Capitalists Flock to African Healthcare Space - Jaza Rift, accessed July 25, 2025, https://jazarift.com/venture-capitalists-flock-to-african-healthcare-space/

24. How this African startup is using AI to close data gaps in healthcare - Google Blog, accessed July 25, 2025, https://blog.google/intl/en-africa/company-news/outreach-and-initiatives/the-kenyan-startup-using-ai-to-close-data-gaps-in-healthcare/

25. Africa Open Lab | GSK, accessed July 25, 2025, https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/africa-open-lab/

26. Center for Innovative Drug Development and Therapeutic Trials for ..., accessed July 25, 2025, https://bvgh.org/center-for-innovative-drug-development-and-therapeutic-trials-for-africa/

27. Harmonized Tools for Clinical Trial Regulation in Africa Are Imminent, accessed July 25, 2025, https://globalforum.diaglobal.org/issue/december-2018/harmonized-tools-for-clinical-trial-regulation-in-africa-are-imminent/

28. pmc.ncbi.nlm.nih.gov, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12227291/#:~:text=The%20ethical%2C%20legal%20and%20social,et%20al.%2C%202015).

29. Challenges Facing Research Ethics Committees in Africa ..., accessed July 25, 2025, https://www.innovations-report.com/education/studies-and-analyses/report-77339/

30. Informed consent approaches for clinical trial participation of infants with minor parents in sub-Saharan Africa: A systematic review | PLOS One - Research journals, accessed July 25, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237088

31. Informed Consent in West Africa: Bridging Regulatory Compliance and Cultural Diversity, accessed July 25, 2025, https://globalforum.diaglobal.org/issue/april-2025/informed-consent-in-west-africa-bridging-regulatory-compliance-and-cultural-diversity/

32. Strengthening clinical trials in African primary care - PMC, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11304206/

33. Breaking the barriers for conducting clinical trials in Africa: A need for higher commitment and collaborations - PMC, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12110202/

34. What's next for R&D in health for Africa? - Brookings Institution, accessed July 25, 2025, https://www.brookings.edu/articles/whats-next-for-rd-in-health-for-africa/

35. The importance of funding and investment to strengthen data science in Africa - PMC, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12259852/

36. Meeting Report: Optimizing Efficiency and Impact in the African ..., accessed July 25, 2025, https://africacdc.org/download/meeting-report-optimizing-efficiency-and-impact-in-the-african-clinical-trials-ecosystem/

37. African Medicines Agency (AMA) - Clinical Trials Community Africa ..., accessed July 25, 2025, https://www.ctc.africa/ama

38. African Medicines Agency (AMA) | AUDA-NEPAD, accessed July 25, 2025, https://www.nepad.org/microsite/african-medicines-agency-ama

39. Landmark Agreement Among Africa's Leading National Medicines ..., accessed July 25, 2025, https://africacdc.org/news-item/landmark-agreement-among-africas-leading-national-medicines-regulatory-authorities-to-foster-collaboration/

40. Africa Achieves Full Regional Regulatory Harmonization, Marking a new chapter of same medicine standards across the continent | AUDA-NEPAD, accessed July 25, 2025, https://www.nepad.org/news/africa-achieves-full-regional-regulatory-harmonization-marking-new-chapter-of-same

41. Africa Medicines Agency: No Longer a Vision, But a Vital Reality, accessed July 25, 2025, https://www.saafrica.org/pages/2025/07/15/africa-medicines-agency-no-longer-a-vision-but-a-vital-reality/

42. African Medicines Agency (AMA) to Hold Second Ordinary Session of the Conference of State Parties in Kigali, accessed July 25, 2025, https://au.int/en/newsevents/20250602/african-medicines-agency-ama-hold-second-ordinary-session-conference-state

43. AMRH Home | AUDA-NEPAD- AMRH, accessed July 25, 2025, https://amrh.nepad.org/

44. Digital Health Innovations in Africa: Harnessing AI ... - Frontiers, accessed July 25, 2025, https://www.frontiersin.org/research-topics/62391/digital-health-innovations-in-africa-harnessing-ai-telemedicine-and-personalized-medicine-for-improved-healthcare

45. Health care in Africa: Emerging technologies at play - Brookings Institution, accessed July 25, 2025, https://www.brookings.edu/articles/health-care-in-africa-emerging-technologies-at-play/

46. Public-private partnerships: Unlocking new opportunities in West ..., accessed July 25, 2025, https://www.thecable.ng/public-private-partnerships-unlocking-new-opportunities-in-west-african-healthcare/

47. Are public–private partnerships the future of healthcare delivery in sub-Saharan Africa? Lessons from Lesotho | BMJ Global Health, accessed July 25, 2025, https://gh.bmj.com/content/4/2/e001217

48. Meet the Healthcare Start-ups That Won the Africa Innovation Challenge 2.0, accessed July 25, 2025, https://www.jnj.com/innovation/meet-the-healthcare-start-ups-that-won-the-africa-innovation-challenge-2-0

49. Investing in African health tech can transform health systems. Here's how - Gavi, the Vaccine Alliance, accessed July 25, 2025, https://www.gavi.org/vaccineswork/investing-african-health-tech-can-transform-health-systems-heres-how

50. Analysis of African Digital Health Startup Failures and Strategies for Success, accessed July 25, 2025, http://www.college.doctorsexplain.net/blog/details/analysis-of-african-digital-health-startup-failures-and-strategies-for-success/364

51. Strengthening clinical trial capabilities and epidemic preparedness ..., accessed July 25, 2025, https://www.nihr.ac.uk/blog/strengthening-clinical-trial-capabilities-and-epidemic-preparedness-africa

52. EDCTP: Home, accessed July 25, 2025, http://www.edctp.org/

53. Financing Health Innovation in Africa | Think Global Health, accessed July 25, 2025, https://www.thinkglobalhealth.org/article/financing-health-innovation-africa

54. Cancer Research Funding in Africa - PMC - PubMed Central, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12234859/

55. Expanding Access to Healthcare in Africa - International Finance Corporation, accessed July 25, 2025, https://www.ifc.org/content/dam/ifc/doc/2023-delta/mas-healthcare-factsheet-2023.pdf

56. Tech And Health Industries Contribute Billions To South Africa's VC Sector, Report Finds, accessed July 25, 2025, https://www.forbesafrica.com/current-affairs/2025/07/24/tech-and-health-industries-contribute-billions-to-south-africas-vc-sector-report-finds/

57. Ethics | WHO | Regional Office for Africa, accessed July 25, 2025, https://www.afro.who.int/health-topics/ethics

58. Ethics & Regulatory Affairs - EDCTP, accessed July 25, 2025, http://www.edctp.org/ethics-regulatory-affairs/

59. Informed consent in clinical trials | South African Journal of Bioethics and Law, accessed July 25, 2025, https://samajournals.co.za/index.php/sajbl/article/view/301

60. Optimising informed consent for participants in a randomised controlled trial in rural Uganda: a comparative prospective cohort mixed-methods study, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6304001/

61. Improving the Informed Consent Process for Research Subjects with Low Literacy: A Systematic Review | Request PDF - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/publication/229064917_Improving_the_Informed_Consent_Process_for_Research_Subjects_with_Low_Literacy_A_Systematic_Review

62. Linguistic Strategies for Improving Informed Consent in Clinical Trials Among Low Health Literacy Patients | JNCI: Journal of the National Cancer Institute | Oxford Academic, accessed July 25, 2025, https://academic.oup.com/jnci/article/109/3/djw233/2905672

63. Community engagement in research in Sub Saharan Africa: current practices, barriers, facilitators, ethical considerations and the role of gender - a systematic review - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/publication/365775067_Community_engagement_in_research_in_Sub_Saharan_Africa_current_practices_barriers_facilitators_ethical_considerations_and_the_role_of_gender_-_a_systematic_review

64. The African Health Research Agenda Should Focus on Delivering More Health Outcomes, accessed July 25, 2025, https://africacdc.org/news-item/the-african-health-research-agenda-should-focus-on-delivering-more-health-outcomes/

65. (PDF) A compound analysis of medical device clinical trials registered in Africa on clinicaltrials.gov - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/publication/384637847_A_compound_analysis_of_medical_device_clinical_trials_registered_in_Africa_on_clinicaltrialsgov

66. African Medicines Innovations and Technology Development Platform, accessed July 25, 2025, https://www.tia.org.za/technology-platforms/african-medicines-innovations-and-technology-development-platform/

67. How Rwanda is using Artificial Intelligence to improve healthcare, accessed July 25, 2025, https://www.afdb.org/en/success-stories/how-rwanda-using-artificial-intelligence-improve-healthcare-55309

68. Strengthening Africa's Policy and Regulatory Frameworks with the AU Model Law, accessed July 25, 2025, https://www.nepad.org/news/strengthening-africas-policy-and-regulatory-frameworks-au-model-law

69. The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations - PMC - PubMed Central, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11520252/

70. (PDF) Establishment of the African Medicines Agency: progress, challenges and regulatory readiness - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/publication/349904795_Establishment_of_the_African_Medicines_Agency_progress_challenges_and_regulatory_readiness

71. Africa CDC and Global Health EDCTP3 sign Memorandum of Understanding to promote public health in Africa, accessed July 25, 2025, https://www.global-health-edctp3.europa.eu/news-and-events/news/africa-cdc-and-global-health-edctp3-sign-memorandum-understanding-promote-public-health-africa-2025-02-17_en

72. WHO Innovation hub - World Health Organization (WHO), accessed July 25, 2025, https://www.who.int/teams/digital-health-and-innovation/who-innovation-hub

73. Research for health: A strategy for the African region, 2016-2025, accessed July 25, 2025, https://www.afro.who.int/publications/research-health-strategy-african-region-2016-2025

74. Increasing the visibility of the African clinical trialists and sites - YouTube, accessed July 25, 2025, https://www.youtube.com/watch?v=RQpag947fcc

75. Launch of the African Academy of Science's Strategic Plan 2023 – 2027 - YouTube, accessed July 25, 2025, https://www.youtube.com/watch?v=-9md1YsAzkg

76. The African Academy of Sciences (AAS), accessed July 25, 2025, https://portal.aasciences.app/storage/publications/24092024014903AAS%20Brochure%20-%20Final%20September%202024.pdf

77. Research Areas - Africa Pandemic Sciences Collaborative, accessed July 25, 2025, https://www.africapandemicsciences.org/clinical-research-and-trials

78. Effective Community Engagement in Global Health Research for Sustainable Change in Africa - YouTube, accessed July 25, 2025, https://www.youtube.com/watch?v=UqHBg5Sxhbw

79. Journal of Public Health in Africa – Africa CDC, accessed July 25, 2025, https://africacdc.org/journal-of-public-health-in-africa/

80. Journal of Public Health in Africa – Africa CDC, accessed July 25, 2025, https://www.africacdc.org/journal-of-public-health-in-africa/

81. AFRICAN JOURNAL OF HEALTH SCIENCES - KEMRI, accessed July 25, 2025, https://www.kemri.go.ke/african-journal-of-health-sciences/

82. Pan African Medical Journal - ScienceOpen, accessed July 25, 2025, https://www.scienceopen.com/collection/dbf2a419-69ec-479b-b8a7-682e2a59b522

83. International Compilation of Human Research Standards ... - HHS.gov, accessed July 25, 2025, https://www.hhs.gov/sites/default/files/ohrp-international-compilation-africa-2024.pdf